[8-K] Lyra Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Lyra Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement (Listing Rule 5550(a)(2)). The company received written confirmation from Nasdaq on June 13, 2025 that its common stock maintained a bid price above $1.00 for 12 consecutive business days from May 28, 2025 to June 12, 2025.

Key details:

• Trading Symbol: LYRA on Nasdaq Capital Market
• Stock Type: Common Stock ($0.001 par value per share)
• Company Status: Emerging growth company
• Compliance Issue: Now resolved and closed

This development removes a significant regulatory concern for the company and ensures continued listing on the Nasdaq Capital Market. The filing was signed by CFO Jason Cavalier on June 23, 2025.

Positive

• Company regained Nasdaq listing compliance by maintaining share price above $1.00 for 12 consecutive trading days, removing delisting risk

Negative

• None.

Insights

Capital Markets Compliance Expert

Lyra regained Nasdaq compliance by maintaining $1+ share price for 12 days, removing delisting threat and stabilizing trading status.

Lyra Therapeutics has successfully regained compliance with Nasdaq's Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of $1.00 per share. The company received confirmation from Nasdaq on June 13, 2025, noting that Lyra's common stock had maintained the required minimum price for 12 consecutive business days (May 28 through June 12, 2025).

This development is significant for several reasons. First, it removes the immediate threat of delisting that typically follows prolonged periods below the $1.00 threshold. Companies that fail to regain compliance often face potential delisting, reverse stock splits, or other potentially dilutive capital restructuring measures to artificially boost share price.

For Lyra, as an emerging growth company in the biotech sector, maintaining Nasdaq listing is particularly crucial for ensuring continued access to capital markets, institutional investor participation, and overall market liquidity. The regained compliance indicates some level of price stabilization and potentially improved market confidence in the company's prospects.

While this development resolves the immediate compliance concern, investors should note that this represents a minimum maintenance requirement rather than a fundamental business improvement. The filing provides no information about the factors that helped the stock price recover above the threshold, whether it was driven by positive operational developments, general market trends, or specific corporate actions.

NASDAQ false 0001327273 0001327273 2025-06-13 2025-06-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2025

Lyra Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-39273		84-1700838
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

480 Arsenal Way
Watertown, Massachusetts		02472
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 393-4600

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		LYRA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On June 13, 2025, Lyra Therapeutics, Inc. (the “Company”) received written notice from The Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company that the Company’s common stock, par value $.001 per share, maintained a minimum bid price of $1.00 or more for 12 consecutive business days, from May 28, 2025 to June 12, 2025. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and the matter has been closed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Lyra Therapeutics, Inc.
Date: June 23, 2025				By:		/s/ Jason Cavalier
						Jason Cavalier, Chief Financial Officer

FAQ

Why did LYRA receive a notice from Nasdaq on June 13, 2025?

LYRA received notice from Nasdaq confirming that the company had regained compliance with Listing Rule 5550(a)(2) after maintaining a minimum bid price of $1.00 or more for 12 consecutive business days, from May 28, 2025 to June 12, 2025.

Was LYRA at risk of being delisted from Nasdaq?

While the filing doesn't explicitly state a prior delisting risk, the fact that LYRA had to regain compliance with Nasdaq's minimum bid price requirement (Rule 5550(a)(2)) suggests the company had previously fallen below the $1.00 minimum bid requirement, which can lead to delisting if not resolved.

What is LYRA's current listing status on Nasdaq?

As of June 13, 2025, LYRA is in full compliance with Nasdaq listing requirements, specifically Listing Rule 5550(a)(2) regarding minimum bid price, and the matter has been closed. The company's common stock continues to trade on The Nasdaq Capital Market under the symbol 'LYRA'.

How long did LYRA need to maintain its stock price above $1.00 to regain Nasdaq compliance?

LYRA needed to maintain its stock price at $1.00 or above for 12 consecutive business days to regain compliance. The company achieved this requirement during the period from May 28, 2025 to June 12, 2025.